Skip to Main Content

Paper Details

Pharmacological inhibition of BCL-2 with the FDA-approved drug venetoclax impairs longitudinal bone growth.
Sci Rep
2
2023
BCL-2, Chondrogenic ATDC5 cells, Mice, Venetoclax, cancer, cancer cells, childhood cancer, children, chondrocytes, ex, growth plate chondrocytes, hematological malignancies, human, mice, normal bone cells, patients, rat, venetoclax
Author NameAffiliation
Claes OhlssonDepartment of Internal Medicine and Clinical Nutrition, Institute of Medicine, University of Gothenburg
Claes OhlssonDepartment of Internal Medicine and Clinical Nutrition, Institute of Medicine, University of Gothenburg
  • 1 - 2

Datasets

Release 1.2